Company Filing History:
Years Active: 2024-2025
Title: Innovations by Inventor Bryan Choi
Introduction
Bryan Choi is an accomplished inventor based in Boston, MA. He has made significant contributions to the field of cancer treatment through his innovative research and patented inventions. With a total of 2 patents, Choi is recognized for his work in developing advanced therapeutic methods.
Latest Patents
Choi's latest patents include groundbreaking inventions aimed at improving cancer treatment. One of his notable patents is for "Chimeric antigen receptor T cells targeting the tumor microenvironment." This invention provides methods and compositions for treating cancer by specifically targeting the tumor microenvironment. Another significant patent is for "T cells expressing a chimeric antigen receptor." This patent describes methods for producing T cells that comprise chimeric antigen receptors (CAR) with a portion of the extracellular domain of a Tumor Necrosis Factor (TNF) superfamily receptor ligand. These CAR T cells are designed to overcome resistance to anti-BCMA targeted therapies and utilize dimerizing and trimerizing transmembrane domains for optimal function. This invention is also related to methods of treating cancer, plasma cell diseases, or autoimmune diseases.
Career Highlights
Bryan Choi is currently associated with The General Hospital Corporation, where he continues to advance his research in cancer therapies. His work has garnered attention for its potential to revolutionize treatment options for patients suffering from various forms of cancer.
Collaborations
Choi collaborates with notable professionals in his field, including Marcela V Maus, enhancing the impact of his research through shared expertise and innovative ideas.
Conclusion
Bryan Choi's contributions to cancer treatment through his patented inventions highlight his role as a leading inventor in the medical field. His innovative approaches have the potential to significantly improve patient outcomes and advance therapeutic techniques.